Table 1

Patient characteristics at baseline and at 2-year follow-up

Variable

n

Baseline

At 2-year follow-up


Demographic

Age (years)

215

57.4 (49.1–64.7)

Female

215

170 (79.0%)

Menopause

170

111 (65.3%)

Body mass index (kg/m2)

215

23.9 (21.3–26.2)

24.0 (21.5–26.2)

Smoker

210

65 (31.0%)

67 (31.9%)

Disease

Disease duration (years)

215

9 (4–16)

Age at disease onset (years)

215

45.0 (33.0–53.0)

Rheumatoid factor-positive

202

97 (48.0%)

Physician's global assessment score (visual analogue scale, 0–100 mm)

203

19.0 (8.0–39.8)

17.6 (8.5–30.0)

Modified Health Assessment Questionnaire (range 1–4)

214

1.50 (1.13–1.75)

1.50 (1.13–1.87)

Erythrocyte sedimentation rate (mm/hour)

210

16 (9–27)

14 (8–27)

Disease activity score including 28 joints

202

4.04 (3.17–4.96)

4.26 (3.36–5.06)

Medication

Ever user of disease-modifying antirheumatic drugs

213

177 (83.1%)

177 (83.1%)

Corticosteroids

208

79 (37.9%)

85 (40.9%)

User of corticosteroids in the 2-year period

208

93 (44.7%)

Antiresorptive osteoporosis treatment

209

47 (22.5%)

68 (32.5%)

Ever user of antiresorptive osteoporosis treatment

209

92 (44.0%)

Calcium and/or vitamin D

210

113 (53.8%)

155 (73.8%)


Data presented as the median (interquartile range) or as the absolute value (%).

Hoff et al. Arthritis Research & Therapy 2007 9:R81   doi:10.1186/ar2280

Open Data